Year None202420232022202120202019201820172014 Mar 27, 2024 PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors Mar 18, 2024 PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer Feb 29, 2024 PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights Feb 26, 2024 PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference Jan 18, 2024 PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway Jan 05, 2024 PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development